|
|
|
|
|
1.
3599 Accesses
|
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice
Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, David Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013)
Abstract | Provisional PDF
| PubMed
|
Editor’s summary
Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
|
|
|
2.
1068 Accesses
|
5-HT6 receptors and Alzheimer's disease
María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT6 receptor compounds, resulting in 5-HT6-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
|
|
|
3.
1004 Accesses
|
Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
|
|
|
4.
970 Accesses
|
Advances in blood-based protein biomarkers for Alzheimer's disease
Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
|
|
|
5.
955 Accesses
|
Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
|
|
|
6.
800 Accesses
|
Modeling Alzheimer's disease with non-transgenic rat models
Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
|
|
|
7.
731 Accesses
|
Alcohol-related dementia: an update of the evidence
Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
|
|
|
8.
723 Accesses
|
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
|
|
9.
545 Accesses
|
Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
|
|
|
10.
541 Accesses
|
Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease
Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013)
Abstract | Full text | PDF
| PubMed
|
|
|
11.
511 Accesses
|
DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease
Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
|
|
|
12.
483 Accesses
|
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems
Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
|
|
|
13.
444 Accesses
|
Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?
Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
|
|
|
14.
442 Accesses
|
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
|
|
|
15.
385 Accesses
|
Modeling the heterogeneity in risk of progression to Alzheimer's disease across
cognitive profiles in mild cognitive impairment
Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
|
|
|
16.
382 Accesses
|
18F-florbetaben Aβ imaging in mild cognitive impairment
Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
|
|
|
17.
372 Accesses
|
The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection
Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
|
|
|
18.
355 Accesses
|
Mild traumatic brain injury: a risk factor for neurodegeneration
Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central |
|
Editor’s summary
Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
|
|
|
19.
342 Accesses
|
Plasma tau levels in Alzheimer's disease
Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013)
Abstract | Full text | PDF
| PubMed
|
|
|
20.
329 Accesses
|
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman, Thomas J Montine, Jeffrey L Cummings, Greg M Cole Alzheimer's Research & Therapy 2012, 4:43 (29 October 2012)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
Oral curcumin did not lead to changes in cognitive examinations or plasma biomarker levels in a 24-week randomized, double blind, placebo-controlled study in patients with Alzheimer disease (AD).
|
|
|
21.
306 Accesses
|
Predicting progression of Alzheimer's disease
Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
|
|
|
22.
295 Accesses
|
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
|
|
|
23.
297 Accesses
|
Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains
Brenda D Moore, Paramita Chakrabarty, Yona Levites, Tom L Kukar, Ann-Marie Baine, Tina Moroni, Thomas B Ladd, Pritam Das, Dennis W Dickson, Todd E Golde Alzheimer's Research & Therapy 2012, 4:18 (23 May 2012)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
Extensive overlapping between amyloid β (Aβ) levels found in pathological ageing (PA) and Alzheimer's disease (AD) brains indicates that PA represents a prodromal stage of AD or resistance to toxic effects of Aβ.
|
|
|
24.
279 Accesses
|
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Todd E Golde, Wolfgang J Streit, Paramita Chakrabarty Alzheimer's Research & Therapy 2013, 5:24 (21 May 2013)
Abstract | Full text | PDF
|
Editor’s summary
Golde and colleagues review the function of innate immune signalling in Alzheimer's disease (AD) following recent studies showing variants of TREM2, a triggering receptor on myeloid cells, is significantly associated with AD risk.
|
|
|
25.
266 Accesses
|
Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease
Margaret M Esiri, Steven A Chance Alzheimer's Research & Therapy 2012, 4:7 (1 March 2012)
Abstract | Full text | PDF
| PubMed
|
Editor’s summary
Esiri and Chance discuss the impact of epidemiological factors on cognitive reserve and cortical plasticity, which act as preventative factors against cognitive decline and the development of Alzheimer's disease (AD) in the elderly.
|